Back to Journals » Journal of Hepatocellular Carcinoma » Volume 2

Fibrolamellar hepatocellular carcinoma: current clinical perspectives

Authors Lafaro K, Pawlik T

Received 24 June 2015

Accepted for publication 16 July 2015

Published 9 October 2015 Volume 2015:2 Pages 151—157


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Ahmed Kaseb

Kelly J Lafaro,1 Timothy M Pawlik2

1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ~1%–9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10–35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC.

Keywords: hepatocellular carcinoma, fibrolamellar, hepatocyte paraffin I, locoregional therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]